shortening the duration of treatment with fixed-duration or mrd-adapted regimens in cll
Published 4 months ago • 66 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
12:46
fixed duration treatment strategies in cll
-
1:32
cll14: feasibility of fixed-duration frontline therapy in cll
-
1:56
the future of fixed-duration therapy in cll
-
0:56
fixed-duration treatment strategies for frontline and relapsed cll
-
1:13
factors to consider when selecting between continuous and fixed-duration therapy in cll
-
2:41
fixed-duration vs continuous therapy in cll
-
5:19
the current treatment landscape for multiple myeloma and trials investigating novel combinations
-
1:08:41
immunophenotyping of acute leukemia - part 2 of 4
-
9:26
phase i/ii study of zilovertamab and ibrutinib in mcl and cll
-
2:18
treating patients with advanced-stage hl in the frontline and relapsed settings in 2024
-
2:08
choosing between continuous versus fixed-duration therapy in cll
-
2:43
insights into phase i/ii study assessing fixed-duration glofitamab treatment for r/r lbcl
-
4:05
comparing continuous and fixed duration therapy in cll
-
2:22
improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
1:05
btk degraders in the treatment of cll
-
1:38
an update on the optic study: adjusting the dose of ponatinib for cp-cml
-
2:24
the effectiveness of ibrutinib flexible dosing regimens on ttnt in cll/sll
-
1:09
current and emerging treatment strategies for cll & defining the optimal treatment duration
-
1:18
advances in cll treatment
-
1:29
the importance of treatment sequencing in cll
-
1:28
the future of cll treatment